Albert David Ltd
Pharmaceuticals & Biotechnology | Small Cap
Albert David Ltd, operating in the Healthcare Services sector, showcases a mixed financial performance. The company exhibits strong solvency and coverage ratios, indicating a solid financial foundation and the ability to meet its obligations. Profitability, particularly Return on Capital Employed and Return on Equity, reflects reasonable returns, although Return on Assets is low. However, liquidity, efficiency, and growth metrics reveal areas of concern. The company's financial health is further supported by stable book value and dividend payouts. While the company demonstrates strengths in certain areas, addressing the weaknesses in liquidity, efficiency, and growth will be crucial for sustained success.
Latest Report
View AllThe Latest Reports Are Not Available at the Moment. We’ll Notify You Once They’re Available.
Latest News
View AllThe Latest News Is Not Available at the Moment. We’ll Notify You Once It’s Available.
- Valuation MetricsNeutral
- Market Metrics
- Stock Reports
- Stock News
- Growth Ratio2.80
- Financial Ratio6.80
- Profitability Ratio5.80
- Efficiency Ratio4.67
- Coverage Ratio10.00
- Solvency Ratio10.00
- Liquidity Ratio2.00
- Peer Assessment
- Management AssessmentBalanced
- Risk AssessmentBalanced
- 1 HourBullish
- 2 HoursBullish
- 4 HoursBullish
- 1 DayNeutral
- 1 WeekBullish
- 1 MonthNeutral
Albert David Ltd, operating in the Healthcare Services sector, showcases a mixed financial performance. The company exhibits strong solvency and coverage ratios, indicating a solid financial foundation and the ability to meet its obligations. Profitability, particularly Return on Capital Employed and Return on Equity, reflects reasonable returns, although Return on Assets is low. However, liquidity, efficiency, and growth metrics reveal areas of concern. The company's financial health is further supported by stable book value and dividend payouts. While the company demonstrates strengths in certain areas, addressing the weaknesses in liquidity, efficiency, and growth will be crucial for sustained success.
Overall Valuation Score
P/E RATIO (TTM)
-271.72
Industry Median
28.93
Small Cap Median
26.92
P/E RATIO
-272.76
P/B RATIO
1.04
Industry Median
3.18
Small Cap Median
2.63
P/S RATIO
1.21
Industry Median
3.41
Small Cap Median
2.40
Others
PEG RATIO
0.00
EV/EBITDA RATIO
26.74
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹711.9 as on Jun 18, 2026.
Unlock Live Chart
Please login to view interactive real-time technical charts powered by TradingView.
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
0.00
Today's Low
0.00
Today's High
The company's growth ratios indicate a mixed performance. While asset growth shows a positive trend, revenue, operating profit, EPS, and net income growth rates are low. This suggests that the company is growing its asset base, but not translating this into increased profitability. The healthcare sector is competitive, and the company needs to focus on strategies to improve its top-line and bottom-line growth.
| Growth Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue Growth Rate | 27.24 | 8.95 | 6.16 | -4.7 | -3.19 |
| Operating Profit Growth Rate | 115.79 | 7.32 | 6.82 | -93.62 | 66.67 |
| Earnings Per Share (EPS) Growth | 59.27 | 2.59 | 108.5 | -77.19 | -108.66 |
| Asset Growth Rate | 17.6 | 5.49 | 17.73 | 2.61 | 1.57 |
| Net Income Growth Rate | 59.09 | 2.86 | 108.33 | -77.33 | -105.88 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
The company's financial ratios present a mixed performance. While the Dividend Per Share and Capital Expenditures are good, the Adjusted EPS, Cash EPS, and Book Value Per Share are average. This suggests that the company is returning value to shareholders through dividends and has adequate capital spending, but its earnings and book value growth are not strong. Improving earnings and book value could enhance overall financial performance.
| Financial Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Adjusted Earnings Per Share (Adjusted EPS) | 55 | 60 | 125 | 28.33 | -1.67 |
| Cash Earnings Per Share (Cash EPS) | 73.33 | 75 | 136.67 | 40 | 15 |
| Book Value Per Share | 466.67 | 520 | 638.33 | 655 | 653.33 |
| Dividend Per Share (DPS) | 9.27 | 8.87 | 11.89 | 5.12 | 5.01 |
| Capital Expenditures (CapEx) | 8.6 | 4.8 | 10.9 | 14.6 | 28.8 |
Adjusted Earnings Per Share (Adjusted EPS)
Cash Earnings Per Share (Cash EPS)
Book Value Per Share
Dividend Per Share (DPS)
Capital Expenditures (CapEx)
The company's profitability ratios present a mixed picture. While Return on Capital Employed and Return on Equity are reasonable, Gross Profit Margin, Operating Margin, and Net Margin are very low. This suggests that the company is generating adequate returns on its capital and equity, but its core profitability margins need improvement. The healthcare sector can be competitive, and improving these margins could enhance overall profitability.
| Profitability Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Gross Profit Margin | 10.22 | 10.26 | 11.05 | -1.16 | -1.5 |
| Return on Capital Employed (ROCE) | 17 | 17 | 28 | 6 | 1 |
| Return on Equity (ROE) | 12.5 | 11.54 | 19.58 | 4.33 | -0.26 |
| Return on Assets (ROA) | 10.22 | 10.4 | 9.44 | 0.59 | 0.96 |
| Operating Margin | 13.1 | 12.9 | 12.98 | 0.87 | 1.5 |
| Net Margin | 11.18 | 10.56 | 20.72 | 4.93 | -0.3 |
Gross Profit Margin
Return on Capital Employed (ROCE)
Return on Equity (ROE)
Return on Assets (ROA)
Operating Margin
Net Margin
The company's efficiency ratios present a mixed picture. While the Days Sales in Inventory and Receivable Days are relatively high, indicating slow inventory turnover and longer collection periods, the other efficiency metrics are very low. This suggests that the company may have challenges in optimizing its asset utilization. The high Days Sales in Inventory and Receivable Days could tie up working capital and affect overall profitability. Improving asset turnover could enhance operational performance.
| Efficiency Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Fixed Asset Turnover Ratio | 3.56 | 4.26 | 4.36 | 3.48 | 3.34 |
| Inventory Turnover Ratio | 7.49 | 6.8 | 6.78 | 6.46 | 5.54 |
| Receivables Turnover Ratio | 14.23 | 12.4 | 12.27 | 12.32 | 10.95 |
| Days Sales in Inventory Ratio | 48.73 | 53.68 | 53.83 | 56.5 | 65.88 |
| Receivable Days | 25.65 | 29.44 | 29.75 | 29.63 | 33.33 |
| Capital Turnover Ratio | 1.11 | 1.09 | 0.94 | 0.87 | 0.85 |
Fixed Asset Turnover Ratio
Inventory Turnover Ratio
Receivables Turnover Ratio
Days Sales in Inventory Ratio
Receivable Days
Capital Turnover Ratio
The company's coverage ratios are strong, indicating a solid ability to meet its interest and dividend obligations. This provides financial stability and reduces the risk of financial distress. These are important for maintaining investor confidence and funding future growth.
| Coverage Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Interest Coverage Ratio | 48 | 52 | N/A | 26 | 1.33 |
| Equity Dividend Coverage Ratio | 6.67 | 7.14 | 11.11 | 5.88 |
Interest Coverage Ratio
Equity Dividend Coverage Ratio
The company's solvency ratios indicate a very strong financial position. With zero debt, the company is entirely financed by equity, providing a solid financial foundation. This conservative capital structure reduces financial risk and provides stability. However, it also suggests that the company might not be leveraging debt to enhance returns, which could be a missed opportunity for growth and increased profitability.
| Solvency Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Debt Ratio | 0.01 | 0 | 0 | 0.01 | 0 |
| Debt to Equity Ratio | 0.01 | 0 | 0 | 0.01 | 0 |
| Equity Ratio | 0.99 | 1 | 1 | 0.99 | 1 |
| Debt To Asset Ratio | 0 | 0 | 0 | 0 | 0 |
Debt Ratio
Debt to Equity Ratio
Equity Ratio
Debt To Asset Ratio
The company's liquidity position is weak, indicating potential challenges in meeting short-term obligations. The current, quick, and cash ratios are all low, suggesting a limited ability to convert assets into cash quickly. This situation could pose risks in managing day-to-day operations and unexpected financial needs. Low operating cash flow ratios further exacerbate these concerns. While the healthcare sector can sometimes have unique working capital cycles, these ratios highlight the need for improved liquidity management.
| Liquidity Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Current Ratio | 1.09 | 1.35 | 1.18 | 1.29 | 1.23 |
| Quick Ratio | 0.76 | 0.88 | 0.8 | 0.74 | 0.77 |
| Cash Ratio | 0.16 | 0.23 | 0.27 | 0.02 | 0.26 |
| Operating Cash Flow Ratio | 0.33 | 0.1 | 0.4 | -0.24 | -0.06 |
Current Ratio
Quick Ratio
Cash Ratio
Operating Cash Flow Ratio
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | Medico Remedies Ltd | 6.61 | 37.70 | Overvalued | 17.00 | 1.58 | 13.00 |
| 2 | Kilitch Drugs (India) Ltd | 6.61 | 21.17 | Neutral | 37.00 | 9.27 | 30.00 |
| 3 | Kopran Ltd | 6.60 | 25.82 | Neutral | 62.00 | 6.30 | 26.00 |
| 4 | SMS Lifesciences India Ltd | 6.59 | 21.78 | Neutral | 45.00 | 70.68 | 19.00 |
| 5 | Infinium Pharmachem Ltd | 6.42 | 26.49 | Neutral | 22.00 | 6.43 | 14.00 |
| 6 | Medicamen Biotech Ltd | 5.73 | 31.76 | Neutral | 20.00 | 6.94 | 10.00 |
| 7 | Aarey Drugs & Pharmaceuticals Ltd | 5.73 | 58.49 | Neutral | 7.00 | 1.40 | 4.00 |
| 8 | Albert David Ltd | 5.63 | -272.76 | Neutral | 5.00 | -2.62 | -1.00 |
| 9 | BPL Ltd | 5.46 | -31.34 | Neutral | -4.82 | -3.00 | -8.55 |
| 10 | Zim Laboratories Ltd | 5.41 | 41.96 | Neutral | 30.00 | 1.11 | 6.00 |
| 11 | Lyka Labs Ltd | 4.77 | -24.93 | Neutral | -4.00 | -9.05 | -10.00 |
| 12 | Nectar Lifescience Ltd | 3.83 | -2.67 | Neutral | -59.00 | -2.95 | -293.00 |
The management of Albert David Ltd. faces notable challenges. While promoter holding is strong and a dividend is maintained, the company's profitability is declining. The significant decrease in compounded profit growth and a low operating profit margin raise concerns about operational efficiency. ROCE, which was previously strong, has also decreased. This mixed performance suggests that the management needs to address profitability and growth issues.
| Category | Metric | Value | Assessment |
|---|---|---|---|
| PROS | Promoter Holding | 62.23% | High promoter holding indicating alignment |
| Dividend Payout (2025) | 17% | Consistent sharing of profits | |
| CONS | Compounded Profit Growth (TTM) | -77% | Significant decline in profit growth |
| Operating Profit Margin (2025) | 1% | Deteriorating operational efficiency |
Financial Performance & Growth
Albert David Ltd. is facing challenges in financial performance and growth. The compounded sales growth is declining, with a TTM of -4%. Profit growth is significantly negative, with a TTM of -77%. The operating profit margin has declined to 1% in Mar 2025. The company's net profit has also turned negative in the recent quarter. This indicates a weakening financial performance.
| Metric | 2014-2016 | 2017-2019 | 2020-2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Compounded Sales Growth | 1% | 2% | 3% | NA | NA | -4% |
| Compounded Profit Growth | 2% | -2% | -20% | NA | NA | -77% |
| OPM % | 11% | 8.33% | 11.33% | 13% | 13% | 1% |
Capital Efficiency & Returns
The capital efficiency and returns of Albert David Ltd. show a mixed trend. While the ROCE was strong in the past, it has declined to 6% in Mar 2025. This indicates a decline in the productivity of capital employed.
| Metric | 2014-2016 | 2017-2019 | 2020-2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| ROCE % | 17.67% | 13.33% | 14.33% | 17% | 28% | 6% |
Financial Health & Prudence
The company exhibits good financial health and prudence. Debt is minimal, with borrowings consistently low. There is no interest to be paid, indicating low financial leverage. The company has a consistent dividend payout history.
| Metric | 2014-2016 | 2017-2019 | 2020-2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Borrowings | 29.33 | 19.33 | 4.67 | 5 | 3 | 12 |
| Dividend Payout % | 17.67 | 21.67 | 16.67 | 14 | 9 | 17 |
Shareholding & Ownership Structure
The shareholding and ownership structure of Albert David Ltd. is strong. The promoter holding is consistently high, around 62%. FII holding is increasing, and DII holding is stable. Overall, the shareholding pattern indicates confidence in the company.
| Metric | Mar 2017-Mar 2019 | Mar 2020-Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|
| Promoter Holding | 60.90% | 61.72% | 62.04% | 62.13% | 62.23% |
| FII Holding | 0.04% | 0.25% | 0.57% | 0.98% | 1.00% |
| DII Holding | 4.55% | 3.67% | 2.80% | 1.67% | 1.64% |
Albert David Ltd. demonstrates a moderate risk profile. The company faces risks related to declining financial performance, particularly negative profit growth and reduced operating margins. The increase in inventory days also poses a risk, indicating potential inefficiencies in working capital management. However, the company benefits from low debt levels and a high promoter holding, which provide some stability.
Working Capital Management
The working capital management of Albert David Ltd. shows some inefficiencies. Inventory days increased to 201 in Mar 2025, indicating that the company is taking longer to convert inventory into sales. The cash conversion cycle has also increased, suggesting a longer time to convert resources into cash.
| Metric | 2014-2016 | 2017-2019 | 2020-2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Inventory Days | 184.67 | 180.33 | 135 | 149 | 126 | 201 |
| Cash Conversion Cycle | 112.67 | 115.33 | 61 | 87 | 58 | 112 |
Foreign exchange or interest rate exposure
The company has minimal debt and no interest payments. This reduces the risk associated with interest rate fluctuations.
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 1 Hour Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 10713.09Bullish
- SMA 20712.10Bullish
- SMA 50713.12Bullish
- EMA 10713.48Bullish
- EMA 20713.45Bullish
- EMA 50713.12Bullish
- DEMA 10713.98Bullish
- DEMA 20713.22Bullish
- DEMA 50713.89Bullish
- TEMA 10714.84Bullish
- TEMA 20712.95Bullish
- TEMA 50714.75Bullish
- MACD-0.08Bullish
- ADX14.50Weak Trend
- IndicatorValueSignal
- RSI56.02Neutral
- CCI129.33Overbought
- ROC 90.90Bullish
- ROC 141.35Bullish
- ROC 25-0.44Bearish
- Stoch K57.38Neutral
- Stoch D49.13Neutral
- IndicatorValueSignal
- BB Upper718.22Overbought
- BB Middle712.10Neutral
- BB Lower705.97Neutral
- ATR5.50High Volatility
- IndicatorValueSignal
- MFI24.54Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 2 Hours Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bullish
- IndicatorValueSignal
- SMA 10712.32Bullish
- SMA 20715.45Bullish
- SMA 50711.08Bullish
- EMA 10713.63Bullish
- EMA 20713.21Bullish
- EMA 50712.84Bullish
- DEMA 10714.11Bullish
- DEMA 20714.09Bullish
- DEMA 50711.36Bullish
- TEMA 10714.71Bullish
- TEMA 20713.99Bullish
- TEMA 50713.77Bullish
- MACD0.59Bullish
- ADX11.09Weak Trend
- IndicatorValueSignal
- RSI55.20Neutral
- CCI0.34Neutral
- ROC 91.76Bullish
- ROC 14-0.77Bearish
- ROC 253.55Bullish
- Stoch K55.21Neutral
- Stoch D52.30Neutral
- IndicatorValueSignal
- BB Upper728.57Neutral
- BB Middle715.45Neutral
- BB Lower702.33Neutral
- ATR8.70Low Volatility
- IndicatorValueSignal
- MFI16.76Oversold
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 4 Hours Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 10716.38Bullish
- SMA 20710.21Bullish
- SMA 50711.58Bullish
- EMA 10714.02Bullish
- EMA 20713.06Bullish
- EMA 50714.24Bullish
- DEMA 10715.23Bullish
- DEMA 20713.56Bullish
- DEMA 50714.30Bullish
- TEMA 10715.08Bullish
- TEMA 20716.29Bullish
- TEMA 50N/AN/A
- MACD0.60Bullish
- ADX9.76Weak Trend
- IndicatorValueSignal
- RSI53.18Neutral
- CCI44.16Neutral
- ROC 9-1.59Bearish
- ROC 142.63Bullish
- ROC 251.88Bullish
- Stoch K55.07Neutral
- Stoch D51.59Neutral
- IndicatorValueSignal
- BB Upper733.17Neutral
- BB Middle710.21Neutral
- BB Lower687.24Neutral
- ATR14.04Low Volatility
- IndicatorValueSignal
- MFI62.08Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 33 Technical Indicators From The 1 Day Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 10707.44Bullish
- SMA 20709.91Bullish
- SMA 50721.68Bearish
- SMA 100703.96Bullish
- SMA 200745.49Bearish
- EMA 10710.79Bullish
- EMA 20712.63Bearish
- EMA 50713.65Bearish
- EMA 100719.86Bearish
- EMA 200758.73Bearish
- DEMA 10710.53Bullish
- DEMA 20708.87Bullish
- DEMA 50713.75Bearish
- DEMA 100695.69Bullish
- DEMA 200665.52Bullish
- TEMA 10713.22Bearish
- TEMA 20706.24Bullish
- TEMA 50718.37Bearish
- TEMA 100716.09Bearish
- TEMA 200672.33Bullish
- MACD-2.55Bullish
- ADX9.22Weak Trend
- IndicatorValueSignal
- RSI49.35Neutral
- CCI9.82Neutral
- ROC 140.49Bullish
- ROC 25-0.68Bearish
- Stoch K51.03Neutral
- Stoch D59.94Neutral
- IndicatorValueSignal
- BB Upper728.11Neutral
- BB Middle709.91Neutral
- BB Lower691.71Neutral
- ATR23.30Low Volatility
- IndicatorValueSignal
- MFI65.36Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 21 Technical Indicators From The 1 Week Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 20703.35Bullish
- SMA 50764.50Bearish
- EMA 20718.40Bullish
- EMA 50774.77Bearish
- DEMA 20699.97Bullish
- DEMA 50668.33Bullish
- TEMA 20719.43Bullish
- TEMA 50651.85Bullish
- MACD-11.21Bullish
- ADX18.56Weak Trend
- IndicatorValueSignal
- RSI47.36Neutral
- CCI-62.19Neutral
- ROC 146.70Bullish
- ROC 25-2.41Bearish
- Stoch K56.33Neutral
- Stoch D54.97Neutral
- IndicatorValueSignal
- BB Upper779.00Neutral
- BB Middle703.35Neutral
- BB Lower627.70Neutral
- ATR54.37Low Volatility
- IndicatorValueSignal
- MFI58.37Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 25 Technical Indicators From The 1 Month Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 6691.08Bullish
- SMA 12758.25Bearish
- SMA 24970.62Bearish
- EMA 6708.97Bearish
- EMA 12767.42Bearish
- EMA 24843.27Bearish
- DEMA 6671.12Bullish
- DEMA 12657.47Bullish
- DEMA 24780.91Bearish
- TEMA 6690.01Bullish
- TEMA 12633.53Bullish
- TEMA 24651.85Bullish
- MACD8.35Bearish
- ADX20.90Weak Trend
- IndicatorValueSignal
- RSI48.07Neutral
- CCI-33.74Neutral
- ROC 25-40.76Bearish
- ROC 5033.49Bullish
- Stoch K6.10Oversold
- Stoch D28.88Neutral
- IndicatorValueSignal
- BB Upper1321.36Neutral
- BB Middle878.26Neutral
- BB Lower435.17Neutral
- ATR156.62Low Volatility
- IndicatorValueSignal
- MFI53.82Neutral